source
- AI becomes core to biopharma R&D, driving efficiency and faster drug developmentAI is now regarded as essential to everyday operations in the biopharma sector, helping to reduce the time and cost of drug development. Pfizer CEO Albert Bourla said AI played a key role in integ…
- Amgen reports positive Phase 3 results for Sjögren's drug; Novartis announces $900M radioligand partnershipAmgen said its CD40 ligand antagonist dazodalibep met the primary endpoint in a Phase 3 trial for Sjögren's syndrome, marking a notable achievement for the company. Novartis disclosed a $900 milli…